abstract PURPOSE Biomarkers for treatment personalization in metastatic castration-resistant prostate cancer (mCRPC) could help improve patient outcomes. Multiple tests on blood have reported associations with poorer outcome, including serum lactate dehydrogenase (LDH), chromogranin A (CGA), neutrophil:lymphocyte ratio (NLR), and, recently, copy number (CN) of androgen receptor (AR) in plasma DNA. Biologic data suggest an association between choline uptake and AR signaling. We aimed to integrate 18 F -fluorocholine (FCH) uptake on positron emission tomography/computed tomography (PET/CT) scanning with plasma AR CN and other routinely obtained circulating biomarkers to evaluate their association with outcome.
INTRODUCTION
Prostate cancer is the second most common malignancy among men worldwide. 1, 2 The standard treatment for metastatic disease is androgen deprivation therapy, 3 but cancer cells eventually acquire resistance, and castration-resistant prostate cancer (CRPC) develops. It is now widely accepted that the majority of CRPCs are still dependent on the androgen receptor (AR) signaling pathway, 4, 5 and new AR pathway inhibitors such as enzalutamide and abiraterone have shown efficacy against CRPC. [6] [7] [8] [9] Biomarkers for personalizing treatment in metastatic CRPC (mCRPC) could improve patient outcomes. Multiple tests have revealed associations with a poorer outcome, including serum lactate dehydrogenase (LDH), 10 visceral metastasis (especially liver involvement [10] [11] [12] ), chromogranin A (CGA), 13, 14 and neutrophil:lymphocyte ratio (NLR). 15, 16 During the past few years, the potential for plasma DNA analysis to improve clinical practice has substantially increased, with real-time molecular characterization that permits patient stratification and thus facilitates treatment decision making. Plasma AR gain is now acknowledged as a therapy-guiding predictive and prognostic biomarker. [17] [18] [19] [20] [21] 22 Furthermore, recent biologic data suggest an association between choline uptake and AR copy number (CN). 23 Increased AR protein expression and/or signaling has been indirectly related to the upregulation of choline kinase alpha (CHKA), which can bind directly to the AR ligandbinding domain. CHKA could be considered a sort of chaperone for AR, resulting in the ubiquitination and activation of AR-dependent transcription and displaying different functions involved in tumor growth and progression. 23 The overexpression of CHKA protein in multiple tumors, including prostate cancer, leads to an increased uptake of choline and provides the rationale for using 18 F-fluorocholine positron emission tomography/ computed tomography (FCH-PET/CT) in this patient setting. In addition, early FCH-PET/CT has been associated with clinical outcome, independently of the decline in prostate-specific antigen (PSA) in patients with mCRPC treated with abiraterone or enzalutamide. 24, 25 Our aim was to integrate functional imaging, represented as choline uptake in FCH-PET/CT, with plasma AR status, clinical data, and other routinely obtained circulating biomarkers and to evaluate their association with outcome. We did this by combining multiple biomarker approaches to improve the patient treatment selection and to personalize CRPC treatment by stratifying patients according to a specific prognostic score.
MATERIALS AND METHODS

Patients and Molecular Analyses
Between October 2011 and June 2016, 105 patients with CRPC (65 treated with abiraterone and 40 treated with enzalutamide) were considered evaluable for this study. Twenty-six (24.8%) were chemotherapy naive and 79 (75.2%) had previously undergone chemotherapy. All had a histologically confirmed diagnosis of prostate adenocarcinoma treated with abiraterone or enzalutamide in pre-or postchemotherapy settings. Additional selection criteria are specified in the Data Supplement. The study included patients participating in a protocol approved by the Institutional Review Board of Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (REC 2192/2013).
Patients were treated with abiraterone 1,000 mg plus prednisone 5 mg twice per day or enzalutamide 160 mg alone once per day. Treatment was continued until there was evidence of disease progression or unacceptable toxicity. The choice of therapy was at the discretion of the treating physician.
Serum PSA was assessed within 1 week of starting treatment and once per month thereafter. In addition, serum LDH, alkaline phosphatase, complete blood count (used to determine NLR), and serum CGA were also measured within 1 week of starting therapy. Radiographic disease was assessed with CT and bone scans at the time of screening and once every 12 weeks during treatment. In this study, FCH-PET/CT was performed after 12 6 4 weeks of treatment.
Peripheral blood samples were collected from each patient at baseline and at the first radiologic evaluation. Circulating DNA was extracted from 1 to 2 mL of plasma by using the QIAamp Circulating Nucleic Acid Kit (QIAGEN, Santa Clarita, CA). Total extracted plasma DNA was quantified using the Quant-iT high sensitivity PicoGreen doublestranded DNA Assay Kit (Invitrogen) or by spectrophotometric evaluation (NanoDrop ND-1000; Celbio, Milan, Italy). Given the previously demonstrated strong agreement between targeted next-generation sequencing and digital droplet polymerase chain reaction (ddPCR) for CN quantification, 20 we performed an analysis of AR CN using ddPCR on a QX200 ddPCR system (Bio-Rad). For this, we used the AR gene and at least two different reference genes (NSUN3, ElF2C1, or AP3B1) and ZXDB at Xp11.21 as the control gene 20 (Data Supplement).
CONTEXT Key Objective
In the context of multiple biomarkers strategy, we assessed the role of plasma DNA analysis in combination with functional imaging and other routinely obtained circulating biomarkers to perform a better prognostication of metastatic castrationresistant prostate cancer (mCRPC) in patients. Knowledge Generated Androgen receptor copy number detected in plasma, choline-positron emission tomography parameters, and other clinical factors can be considered as independent predictors of overall survival. Our final parsimonious prognostic model from the multivariable analysis of overall survival permitted classification of patients with mCRPC into three risk groups according to the independent prognostic role of these biomarkers. Relevance Our results suggested the potential usefulness of integrating functional imaging with plasma DNA analysis and other noninvasive biomarkers as a tool to improve treatment selection for patients with mCRPC.
PET/CT Imaging FCH-PET/CT was performed on an integrated PET/CT system, and the images were read sequentially using a Xeleris III workstation. Semiquantitative criteria based on the maximum standardized uptake value (SUV max ) and the target:background ratio were used to aid the visual analysis. 26 The metabolic tumor volume (MTV) was calculated as the sum of each 3-dimensional volume of interest. Moreover, for each lesion volume and SUV, the mean was multiplied and then summed to generate the total lesion activity (TLA). MTV is a purely volumetric entity, whereas TLA also takes into account the metabolic activity of the lesion leading to an estimate of tumor activity (Data Supplement).
Statistical Analysis
Data were summarized by frequency for categorical variables and by cutoff using receiver operating characteristic (ROC) curves and median and range for continuous variables. The association between categorical variables was assessed by using the χ 2 test or Fisher's exact test, as appropriate. A comparison between baseline imaging and clinical, laboratory, and molecular features in patients with or without AR gain was performed using the median test (Wilcoxon). ROC curve analysis was performed to estimate the best cutoff value of FCH-PET/CT parameters (TLA, MTV, and SUV max ) and serum CGA level considered as continuous variables.
Progression-free survival (PFS) was measured as the time between the first day of abiraterone or enzalutamide treatment and the date of disease progression or death (whichever came first) or last tumor evaluation. Overall survival (OS) was defined from the date of the start of therapy until death as a result of any cause or last followup visit. Survival curves were traced by the Kaplan-Meier method, and comparisons were based on the log-rank test. Univariable and multivariable Cox regression models were used to investigate potential predictors of PFS and OS and to estimate hazard ratios (HRs) and their 95% CIs. All P values were two-sided, and a P , .05 was considered statistically significant. Statistical analyses were performed with SAS 9.4 software (SAS Institute, Cary, NC).
A Weibull multiple regression model was adopted to evaluate the combined impact of molecular, laboratory, and imaging features on survival. From a full model that contained all the variables, we obtained a final parsimonious model by using a backward selection procedure. The prognostic score was based on the final model, which included six variables. Partial scores were obtained by dividing the value of each regression coefficient by the smallest regression coefficient. The total score for a given patient was obtained by summing the patient's appropriate partial scores, and three groups of patients with different median survival probabilities were identified. If the total score was 2.0 or below, the patient was classified in group I, group II required a score between 2.1 and 4.0, and group III required a score of 4.0 or greater. The choice of time and number of groups with different prognoses was made in terms of clinical consideration, such as time at 15 months (group I at 15 months: OS was greater than 70%; group II at 15 months: OS was 30% to 70%; group III at 15 months: OS was less than 30%).
RESULTS
Association Among Plasma AR Gain, Baseline Increased Metabolic Activity on PET/CT Scan, and Circulating Routine Biomarkers
We detected AR CN gain in plasma from 27 patients with mCRPC (25.7%), three chemotherapy-naive patients (11.5%), and 24 docetaxel-treated patients (30.4%). A summary of overall patient characteristics by AR status is available in the Data Supplement. Patients with AR gain had significantly higher TLA, MTV, and SUV max values (P , .001), number of lesions on FCH-PET/CT scan greater than median value of 12 lesions (P , .001), LDH greater than upper normal value of 225 mU/mL (P = .013), PSA level greater than median value of 29.3 ng/mL (P = .004), and cell-free DNA concentration greater than median value of 38.5 ng/mL (P , .001).
Direct Correlation Between Choline Uptake and PET/CT With Molecular Alterations
We assessed all FCH-PET/CT parameters for each patient and correlated them with other circulating prognostic biomarkers ( Fig 1A) . We identified SUV max as the standard uptake volume, MTV as a pure volumetric entity, and TLA as an indicator of tumor activity (Fig 1B) . The reliability of the data are shown in Figure 1C and the Data Supplement. A strong correlation was observed between SUV max and TLA and MTV (r s = 0.90; P , .001 for both parameters) and between MTV and TLA in both AR normal (r s = 0.94; P , .001) and AR gain patients (r s = 0.85; P , .001). Moreover, the reliability of these data were confirmed, which revealed a particularly evident correlation between TLA and MTV. Figure 1D and the Data Supplement show the median baseline values of TLA, MTV, and SUV max as a function of AR CN in the overall population (P , .001), revealing only a trend in chemotherapy-naive patients, perhaps because of the small number of patients with AR gain.
The ROC curves for the best cutoff value for TLA, MTV, and SUV max were 563,979, 112, and 50, respectively, with 42 (40.0%), 50 (47.6%), and 68 (64.8%) patients showing TLA, MTV, and SUV max values above the cutoff value, respectively. In addition, pretreatment median values for cellfree DNA were also significantly higher in patients with higher TLA, MTV, and SUV max both before and after chemotherapy (Data Supplement). ) between maximum standardized uptake value (SUVmax), total lesion activity (TLA), and metabolic tumor volume (MTV). (D) Association between choline uptake measured as SUV max , TLA, MTV, and circulating androgen receptor (AR) copy number. A box plot is shown with the thick horizontal line depicting the median value of SUVmax, TLA, and MTV in overall, pre-, and postchemotherapy patients. A, AR copy number amplified; CGA, chromogranin A; CHT, chemotherapy, LDH, lactate dehydrogenase; N, AR copy number normal; nCi, nanoCurie; NLR, neutrophil:lymphocyte ratio. and 15.3 months (95% CI, 11.0 to 19.0 months), respectively. In the prechemotherapy group, the median PFS was 7.2 months (95% CI, 4.2 months to not reached), whereas OS was not reached. In the postchemotherapy group, the median PFS was 6.7 months (95% CI, 4.6 to 7.5 months) and the median OS was 13.9 months (95% CI, 10.8 to 18.3 months).
Kaplan-Meier curves were generated to show PFS and OS in patients with CRPC who were treated with chemotherapy (Fig 2) according to AR CN, TLA, and MTV. Chemotherapytreated patients were divided into four prognostic groups according to baseline AR status and TLA, MTV, and SUV max values: AR normal, TLA, MTV, and SUV max low; AR gain, TLA, MTV, and SUV max low; AR normal, TLA, MTV, and SUV max high; and AR gain, TLA, MTV, and SUV max high. They were characterized by a significant difference in PFS (P , .001 for TLA, P = .003 for MTV, and P , .001 for SUV max ) and OS (P , .001 for TLA, P , .001 for MTV, and P , .001 for SUV max ; Data Supplement).
Identification of Imaging, Molecular, and Clinical Features as Independent Predictors of Treatment Outcome
We performed univariable and multivariable Cox proportional hazards regression analysis of OS to evaluate the prognostic impact of different factors. In the univariable analysis, clinical variables such as the presence of visceral metastasis, PSA, alkaline phosphatase, LDH, NLR, serum CGA, previous radical radiotherapy, and the presence of pain were significantly associated with shorter OS in addition to molecular factors (AR CN, cell-free DNA concentration [corresponding to double-stranded DNA (dsDNA)] detected in plasma) and FCH-PET/CT features (MTV, TLA, SUV max , and number of lesions; Table 1 ).
We confirmed these data in the multivariable analysis of OS using a backward stepwise procedure. We showed that AR CN (HR, 1.92; 95% CI, 1.07 to 3.47; P = .029), the presence of visceral metastasis (HR, 3.04; 95% CI, 1.66 to 5.58; P , .001), LDH (HR, 2.95; 95% CI, 1.72 to 5.05; P , .001), NLR (HR, 3.51; 95% CI, 2.14 to 5.74; P , .001), CGA (HR, 3.36; 95% CI, 1.99 to 5.67; P , .001), and MTV (HR, 2.09; 95% CI, 1.25 to 3.50; P = .005; Table 2 ) were significant independent factors. It is possible that the strong correlation among all PET/CT parameters abrogated the statistical significance of TLA and MTV in this analysis.
Combination of Functional Imaging With Circulating Biomarker Analysis to Improve mCRPC Prognostication
Patients were randomly divided into one training set (n = 69) and one validation set (n = 36). The larger two-thirds group of patients was used as a training set to construct the score, and the remaining one third was used as a validation set. Table 2 shows the partial score value for each category, which was obtained by subdividing each regression coefficient by the smallest one as described in Statistical Analysis. The total score for a given patient was obtained by summing the patient's appropriate partial scores, and three groups of patients with different median survival probabilities were identified. If the total score was 2.0 or lower, the patient was classified in group I, group II required a score between 2.1 and 4.0, and group III required a score of 4.0 or greater (Data Supplement). Fig 3A) . Similar results were observed in the validation set (Fig 3B) .
Correlation Between Plasma DNA Analysis and Metabolic Response Assessed by FCH-PET/CT
The prognostic role of plasma AR gain was strongly evident before starting abiraterone or enzalutamide, whereas no variation in AR CN was reported in patients during treatment or upon progression. Figure 4 shows FCH-PET/CT images at baseline and at the first reevaluation of four patients from different prognostic groups according to AR status and TLA, MTV, and SUV max , confirming the impact on survival of the association between baseline AR CN and FCH-PET/TC. A change in dsDNA concentration was reported in relation to the type of response to abiraterone or enzalutamide. We also evaluated PSA response in these groups on the basis of pretreatment AR CN and choline uptake, and we observed no significant association (Data Supplement).
DISCUSSION
This study examined the feasibility of using functional imaging to assess tumor burden and also to evaluate its predictive and prognostic role in CRPC treated with abiraterone or enzalutamide. We confirmed evidence from preclinical and clinical studies showing that CHKA expression and choline production are androgen regulated and that the relationship between CHKA expression, choline uptake, and AR signaling could be used in managing prostate cancer. 23 Within the context of multiple biomarker strategies, including plasma AR, FCH-PET/CT scans, and other well-established prognostic factors in patients with mCRPC, our results show that molecular functional imaging is capable of assessing disease extent and distribution, and it can also contribute to identifying biologic features of overall lesions from patients with CRPC. In this study, we also showed, to our knowledge for the first time, that combining functional imaging and circulating molecular and laboratory parameters can be used to develop a new prognostic stratification tool for CRPC treated with AR-directed therapies.
Currently, numerous drugs in this setting have shown antitumor activity and often lead to a benefit in survival. However, the identification of biomarkers could facilitate personalized next-line systemic therapy in a more accurately selected population. During the past decade, molecular stratification from tissue biopsy has provided several therapeutic targets and prognostic markers, but numerous factors can limit the usefulness of tissue biomarkers (from both primary and secondary tumors). Primary prostate cancer is usually multifocal at the time of diagnosis and often only one tumor clone is responsible for metastasis. This clone may not necessarily be from the largest lesion or the lesion with the highest Gleason grade, as confirmed by the lack of significance of the Gleason score with clinical outcome in our univariable analysis. Moreover, a polyclonal metastasis-to-metastasis seeding may occur during disease progression. 27 Given the complex tumor heterogeneity, assessment of the archival primary tumor or metastatic biopsies for the clinical management of patients with CRPC may not be adequate for or entirely representative of current tumor status. Consequently, alternative approaches, such as blood-based assays and functional imaging may be more feasible because of the possibility of performing serial evaluations during the course of the disease aimed at monitoring tumor dynamics and treatment outcome.
The advantages of using prognostic markers detected by liquid biopsy before starting treatment is now widely acknowledged, especially for AR CN which, unlike AR mutation status, does not noticeably change during ARdirected treatment. 19 For this reason, we considered circulating biomarkers at baseline and did not include the detection of AR mutations, whose frequency is usually too low in pretherapy samples, especially from chemotherapynaive patients. 19, 20 The significant prognostic impact on treatment outcome through the combination of AR status and choline uptake assessed by FCH-PET/CT could lead to the reassessment of prognostic index models for survival that became available over the years in patients with mCRPC treated with standard chemotherapy and hormonal agents. 10, 11 These nomograms use readily available clinical and laboratory factors. In this study, we presented functional molecular imaging as a future potential candidate for developing an updated prognostic model for predicting clinical outcome. The lack of association between AR CN, TLA, MTV, SUV max , and PSA response was likely a result of the characteristic action mechanisms of abiraterone or enzalutamide, which often lead to an unusual PSA modulation. 28, 29 This study has some limitations, the most significant being the variability in the inclusion of chemotherapy-naive and postdocetaxel patients treated with AR-directed therapies (which may have influenced outcome estimates). In addition, this study was a retrospective single-center work. Additional limitations are the small sample size, especially in the prechemotherapy group, and the presence of PET/ CT indices as nonabsolute measures, which can be affected by technical issues such as PET scanner calibration, imaging reconstruction, image acquisition, and timing of tracer administration. Moreover, FCH-PET/CT is still controversial as an imaging tool in clinical practice because of its costs and uncertain diagnostic accuracy. Despite these limitations, our study provided a valuable preliminary insight into the potential usefulness of functional molecular imaging for managing patients with mCRPC. Future biomarker studies will include evaluation of the performance of PET/CT with new promising tracers such as 68 Ga-prostate-specific membrane antigen, which recently proved useful for detecting relapse in patients with biochemical recurrence of prostate cancer after radical treatment 30 and as a prognostic factor for survival outcome in CRPC. 31 Apart from detecting AR mutations, we did not explore other circulating AR aberrations such as AR splice variant-7 (which is associated with outcome in patients with CRPC treated with abiraterone or enzalutamide 32 ) because of the lack of concurrent appropriately collected samples and genomic alterations in DNA defect repair Functional Imaging and Plasma DNA Analysis in CRPC and neuroendocrine differentiation genes, 34, 35 which have recently been shown to drive resistance to androgen suppression.
Another limitation to the interpretation of our data is the clinical utility of cell-free DNA as a prognostic biomarker because of different proportions of tumor DNA constituting the total cell-free DNA concentration (range, 0.01% to 95%). 36 Estimation of tumor content by DNA sequencing and bioinformatic algorithms is warranted in our samples, which could potentially increase the utility of cell-free DNA as a biomarker that, for this reason, we did not consider in our multivariable analysis, 19, 21 and as a reliable complementary approach for disease monitoring.
In conclusion, our study integrated the innovative biomarker approaches of functional imaging and genomics, which contributed to better prognostication, as recently seen for patients with metastatic melanoma 37 and colorectal cancer. 38 Combining different predictive and prognostic biomarker strategies could help to overcome the inter-and intrapatient heterogeneity of CRPC, thus improving patient risk stratification and treatment selection. A larger prospective evaluation is warranted. 
